Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F/TAF (Descovy) once-daily PrEP in men and transgender women at risk of HIV-1
2022-501763-40-00Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: Incidence of HIV-1 infection per 100 person years (primary analysis). Started Jun 2023; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-501763-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501763-40-00.